COINS Act & BINSA: What Chinese Biopharma Leaders Need to Know
An in-depth analysis of the COINS Act and BINSA and their implications for innovation, licensing, investment, and global collaboration.
The first episode of NAPPA Healthcare & Biopharma Insights, NAPPA’s signature thought-leadership webinar series, opens with a focused analysis of two pieces of U.S. legislation reshaping the cross-border biopharma landscape: the COINS Act and BINSA.
Patent attorney Frank Gao (Ladas & Parry LLP), NAPPA’s Midwest Regional Director, leads a one-hour briefing on the legal, IP, and strategic implications for Chinese biopharma companies operating across the U.S.–China corridor — including licensing, technology transfer, investment, and risk mitigation.
The session is open to NAPPA members, partners, and qualified industry guests. Register below to receive Zoom join details.
Key topics.
- ✓ What is the COINS Act?
- ✓ What is BINSA?
- ✓ Impact on Chinese Biopharma Companies
- ✓ Licensing, Technology Transfer & IP Strategy
- ✓ Cross-Border Investment Outlook
- ✓ Opportunities and Risk Mitigation
Understand U.S. legislative developments shaping the cross-border biopharma environment.
Assess the operational implications for biopharma innovation, licensing, and investment.
Navigate global partnerships and U.S. market access with a clear legal lens.
This event has already taken place.
Registration closed on Saturday, July 4, 2026. Thanks to everyone who joined us live. Check the Events page for upcoming episodes in the NAPPA Healthcare & Biopharma Insights series.